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The renin-angiotensin system is activated in acute severe asthma. Angiotensin II causes bronchocon- 
striction in mild asthmatics and potentiates methacholine-evoked bronchoconstriction both in vitro and 
in vivo. 
To evaluate the effect of angiotensin II on histamine-induced bronchoconstriction, human bronchial 
rings (n=6) were obtained from lung tissue at thoracotomy and were prepared in organ baths. 
Contractions were measured isometrically and cumulative concentration-response curves obtained to 
angiotensin II alone and to histamine in the presence and absence of threshold concentrations of 
angiotensin II. 
Eight asthmatic patients with bronchial hyper-reactivity to histamine were challenged with histamine 
during intravenous infusion of placebo, angiotensin II 1 ng kg - ’ min - ’ and angiotensin II 
2ngkg-‘min-1 administered in a randomized, double-blind fashion. FEV, was measured prior to, 
during the infusion and during the histamine challenge. 
Angiotensin II (3 x 10 - 7 M and 10 - 6 M) alone evoked small contractions (CO.25 g) of human bronchi 
in vitro, but pre-incubation with threshold concentrations of angiotensin II (10 - 7 M, 3 x 10 - 7 M and 
1O-6 M) had no effect on histamine-evoked contractions. In asthmatic patients, angiotensin II alone had 
no effect on baseline FEV, at the low levels infused and did not affect the response to nebulized histamine 
as measured by the PCZO histamine: Geometric mean (range) PC,, histamine (mg ml- ‘) screening day 
3.58 (1.26-7.75), placebo infusion 2.67 (0.89-9.57), angiotensin II 1 ng kg - ’ min - ’ 2.45 (0.42-6.97) and 
angiotensin II 2 ng kg- ’ min- ’ 3.09 (0.88-10.78). 
It is concluded that, in contrast to its potentiating effect on methacholine-induced bronchoconstric- 
tion, angiotensin II has no effect on histamine-evoked bronchoconstriction in human bronchi in vitro 
or in vivo. 
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Introduction 
The renin-angiotensin system is activated in acute 
severe asthma with elevation of plasma renin and 
angiotensin II levels (1). Its active octapeptide hor- 
mone angiotensin II, a potent vasoconstrictor, also 
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causes weak bronchoconstriction when administered 
intravenously to mild asthmatics (l), although it is 
not known if this effect is receptor mediated in vivo. 
Angiotensin II can potentiate vagally mediated 
contraction of rabbit airway smooth muscle via a 
prejunctional effect on cholinergic nerve terminals (2) 
and has a postjunctional potentiating effect on sym- 
pathetic contraction of rabbit saphenous artery (3-5). 
It also enhances tissue responses to noradrenaline (6). 
The present authors have shown previously that 
subthreshold concentrations of angiotensin II 
enhance methacholine-induced bronchoconstriction 
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both in vitro and in vivo (7), and endothelin-l-evoked 
bronchoconstriction of bovine airways in vitro, by a 
type-l angiotensin II receptor-specific effect (8). The 
mechanism of this potentiating effect remains obscure 
but the possible interaction with other spasmogens in 
the airway exists. Histamine is a potent bronchocon- 
strictor which is released from mast cells in asthmatic 
airways and therefore is an important spasmogen and 
any potential interaction with angiotensin II would be 
relevant. 
Therefore, the current study examined the effect of 
angiotensin II at subthreshold doses on histamine- 
induced bronchoconstriction in human airways in 
vitro and in vivo. 
Materials and Methods 
IN VITRO 
Tissue Collection and Preparation 
Macroscopically normal human bronchial tissues 
(3rd to 6th order) were obtained from patients 
undergoing thoracotomy for bronchial carcinoma. 
All patients were smokers but information about 
pulmonary function was unavailable; none suffered 
from asthma. Tissues were dissected free of connec- 
tive tissue and fat, and stored overnight at 40°C in 
oxygenated Krebs-Henseleit solution of the following 
composition; NaCl 118.4 mM, KC1 4.7 mM, CaCl, 
2.5 mM, MgSO, 1.2 mM, NaHCO, 24.9 mM, KH,PO, 
1.2 mM and glucose 11.1 mM. Published data has 
shown that overnight storage of this tissue does not 
alter its reactivity (9). 
Measurement of Contractile Responses 
Contractile responses were measured from rings of 
human bronchi (3-5 mm) in vertical organ baths 
(10 ml) at 37 f 0.5”C in oxygenated (95% O,, 5% 
CO,) Krebs-Henseleit solution. Tension (2 g) was 
applied via two platinum wires into the lumen. One 
wire was anchored and the other attached to a force 
displacement transducer (Grass FT03T). Tissues were 
allowed to equilibrate for 2 h during which time 
applied tension was readjusted to the initial level. 
Cumulative concentration-response curves were 
constructed to angiotensin II to ascertain the 
threshold for contraction to this hormone. Angio- 
tensin II produced small (co.25 g maximum), 
concentration-dependent contractions of human 
bronchi, with the threshold for contraction occurring 
between 10 - 7 M and 10 - 6 M (Fig. 1). This compared 
with the maximum contraction of mean (SEM) 1.45 
(0.28) g with 3 x 10 -4 M histamine. 
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FIG. 1. Cumulative concentration-response curve to 
angiotensin II at 10 - a M to 10 - 5 M showing the 
contractile response as milligram tension generated. 
Number of observations (n) = 4. 
In subsequent experiments, cumulative 
concentrationresponse curves were constructed to 
histamine (10 - 9-3 x 10 - 4 M) in the presence and 
absence of angiotensin II (10 - 7 M, 3 X 10 -7 M and 
10 - 6 M). Drugs were added directly to the organ 
bath and angiotensin II was added 15 min before 
histamine concentration-response curves. 
IN VW0 
Patients 
Eight mild asthmatic volunteers (five males) were 
recruited with mean (range) age 41 (27-69) years and 
baseline FEV, 88 (78-106) % of predicted. Bronchial 
hyper-responsiveness to inhaled histamine was 
demonstrated by challenge testing according to the 
method of Cockcroft et al. (10). Individuals found to 
be hypertensive, pregnant or taking antihistamines, 
diuretics or angiotensin-converting enyzme inhibitors 
were excluded. Two subjects were current and one 
was a former smoker. Seven subjects were taking 
inhaled salbutamol as required, four were taking 
additional low dose (<10OO,~g daily) inhaled beclo- 
methasone dipropionate, one was taking additional 
salmeterol and one was on no treatment (Table 1). 
Prior to each study day, subjects were instructed 
to withhold short-acting P-agonists for 8 h and long- 
acting P-agonists for 12 h but inhaled corticosteroids 
were continued unchanged. 
Ethical approval for the study was obtained from 
the Glasgow West Ethical Committee and written, 
informed consent was obtained from the study 
volunteers prior to commencing the study. 
THE EFFECT OF ANGIOTENSIN II ON HISTAMINE-INDUCED BRONCHOCONSTRICTION 611 
TABLE 1. Study patient demographics 
Subject 
Age 
FEV, Histamine 
Sex (years) absolute value (1) (% predicted) PC,, (mg ml - ‘) Treatment 
1 M 27 4.80 (106%) 1.84 S 
2 M 49 3.56 (88%) 4.21 nil 
3 M 32 2.75 (82%) 3.24 S/BDP 
4 F 35 2.83 (98%) 1.26 S/BDP 
5 F 56 2.14 (79%) 2.61 S/BDP 
6 M 30 4.37 (97%) 7.75 S 
7 F 30 2.46 (80%) 5.32 S 
8 M 68 2.46 (78%) 6.33 SIBDPISm 
Mean age: 40.9 3.18 88.5% 3.48” 
(SD): (14.99) (0.97) (10.58) 
S, salbutamol (pm); BDP, beclomethasone dipropionate (< 1000 ,ug day - ‘); Sm, 
salmeterol; *geometric mean. 
Study Pvotocol Measwements 
The study design was randomized, double-blind and 
placebo controlled. The subjects attended the labora- 
tory on four separate occasions; initially for a screen- 
ing visit comprising a physical examination followed 
by a histamine bronchial provocation test. This was 
performed using a Wright’s nebulizer, calibrated to 
give an output of 0.12 ml min- ’ at a flow rate of 
8 lmin-’ air, to define the concentration required to 
cause a 20% fall in FEV, from baseline (the PC,, 
histamine). On the three subsequent visits, an intra- 
venous cannula (Venflon, Viggio AB, Helsinborg, 
Sweden) was inserted into a vein on each forearm; 
after 30 min rest, a blood sample was extracted to 
measure baseline plasma renin and angiotensin II 
levels. Baseline spirometry, pulse, blood pressure 
and pulse oximetry were measured then an intra- 
venous infusion commenced via a 50-ml syringe 
driver (Perfusor Secura E, B.B. Braun, Melsunger 
AG, Germany). Subjects received either placebo (5% 
dextrose) or angiotensin II at subthreshold doses for 
bronchoconstriction of 1 or 2 ng kg - ’ min - ’ over 
1 h. After 30 min, steady state was deemed to have 
been reached and a further blood sample was taken 
from the arm opposite to the infusion and the FEV, 
repeated. A histamine bronchial provocation test was 
then performed and the PC,, noted. At the comple- 
tion of the test, a further blood sample was taken, 
then the bronchoconstriction was reversed with neb- 
ulized salbutamol (Ventolin, Allen and Hanburys, 
U.K.). Throughout the study pulse, blood pressure 
and oxygen saturation were monitored at 15-min 
intervals. 
FEV,. Spirometry was measured using a dry wedge 
spirometer (Vitalograph Model S, Buckinghamshire, 
U.K.), the best of three measurements being taken at 
each time point. 
Pulse and Blood Pressure. A semi-automatic sphy- 
gomomanometer (Dinamap, 1846SX Vital Signs 
Monitor, Critikon, Florida, U.S.A.) was used to 
measure pulse and blood pressure from the opposite 
arm to the infusion at each time point. 
Oxygen Saturation. Oxygen saturation was 
measured by transcutaneous pulse oximetry (Oscar- 
oxy Pulse Oximeter, Datex, Helsinki, Finland) at 
each time point. 
Histamine Bronchial Provocation Test. Baseline 
spirometry was measured then repeated after a 2-min 
inhalation of 0.9% saline, administered via a Wright’s 
nebulizer driven by compressed air, calibrated to 
give an output of 0.12 ml min - ’ at a flow rate of 
8 litres min - ‘. Doubling doses of histamine were 
subsequently administered starting with a dose of 
0.0625 mg ml - ‘. The FEV, was measured at 30, 90 
and 180 s following each inhalation until a 20% fall 
was achieved. The histamine concentration causing a 
20% fall in FEV, was calculated by linear regression 
and taken as the PC,,. 
Angiotensin II Assay. Blood samples were collected 
into iced lo-ml plastic tubes containing EDTA and 
0-phenanthroline inhibitor. They were placed on ice 
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until separation by centrifugation at 3000 g for 
15 min, then the plasma was frozen at - 20°C until 
analysis. The assay for angiotensin II is a modified 
radioimmunoassay which uses C,, cartridges (Sep- 
Pak; Waters, Milford, MA, U.S.A.) to extract angio- 
tensin II from plasma (11). The intra-assay coefficient 
of variation is 6.4% and inter-assay variation 10%. 
The reference range for the authors’ laboratory is 
3-12 pg ml- ’ (2.9-l 1.5 x lop9 M). 
Renin Assay. Blood samples for renin were col- 
lected in 5-ml glass tubes containing EDTA then 
placed on ice and frozen at - 20°C until analysis. 
Plasma renin concentration was measured using an 
antibody trapping technique (12). The intra-assay 
coefficient of variation is 5.5% and the inter-assay 
variation 11% (13). The reference range for the 
authors’ laboratory is 9-50 ,LLU ml ~ ‘. 
Drugs. The drugs used were histamine (Fluka 
Chemicals, Gillingham, U.K. for in vivo studies: 
Sigma Chemicals, Poole, U.K. for in vitro studies) 
and angiotensin II (Sigma Chemicals, U.K.). For the 
in vitro studies, both histamine and angiotensin II 
were prepared as a stock solution in distilled water, 
then serial dilutions were prepared in Krebs- 
Henseleit solution. For in vivo studies, serial dilutions 
of histamine were prepared in phosphate-buffered 
saline ranging from 0.0625 to 8.0 mg ml- ‘. Angio- 
tensin II was prepared in 5% dextrose under sterile 
conditions. 
Statistical Analysis. Statistical significance was 
determined by two-way analysis of variance 
(ANOVA) for in vitro studies and one-way ANOVA 
for in vivo studies with a probability level of PcO.05 
considered significant. Histamine PC,, values were 
transformed logarithmically prior to statistical 
analysis. 
Results 
IN VITRO STUDIES 
Pre-incubation with angiotensin II (10 - 7 M) evoked 
contraction in only two of the six tissues and in both 
cases the contraction was less than 0.1 g compared 
with the control maximum contraction of mean 
1.45 (SEM 0.28) g with histamine (3 x 10p4~). No 
significant enhancement (P>O.O5) of histamine- 
evoked contractions (10 - 9 ~-3 x 10 - 4 M) was seen in 
any of the tissues following pre-incubation with 
angiotensin II at 10p7~, 3 x 10p7~ and 10K6~ 
(Fig. 2). 
1 
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FIG. 2. Cumulative concentration-response curves 
to histamine alone (control, n ) and in the presence 
of angiotensin II at 10e7 M (II), 3 x 10 -’ M (0), 
and 10e6 M (O), showing no significant potentiation 
or attenuation of bronchoconstriction. Number of 
observations (n) = 6 in each case. Responses are 
expressed as a percentage of methacholine (10 - 4 M) 
evoked contraction. 
IN VIL’O STUDIES 
On each of the three study days, there was no 
significant difference between baseline pulse, blood 
pressure, oxygen saturation, FEV,, plasma renin and 
plasma angiotensin II measurements (Table 2). Prior 
to histamine challenge and during the infusion, there 
was no significant change in FEV, noted from base- 
line values on each study day; mean (SEM) change 
in FEV, (1) from baseline: placebo - 0.08 
(0.05), angiotensin II 1 ng kg- ’ min- ’ - 0.12 (0.04), 
angiotensin II 2 ng kg - ’ min - ’ - 0.08 (0.04). 
Following histamine bronchial provocation testing 
on each study day, there was no significant difference 
in histamine PC,, [geometric mean (range)] between 
screening [3.48 (1.26-7.75) mg ml - ‘, placebo 
[2.67 (0.89-9.57), mg ml - ‘, angiotensin II 
1 ngkg-1 min-’ [2.45 (0.42-6.97) mg ml - ‘1 and 
angiotensin II 2 ng kg- ’ min- ’ [3.09 (0.88-10.78) 
mg ml - ‘1 study days (Fig. 3). 
A significant rise (PcO.05) in both systolic 
and diastolic blood pressure occurred following 
infusion of angiotensin II 1 ng kg - ’ min - ’ and 
2ng kg-’ min-1 compared to placebo [systolic BP 
mean (SEM) mmHg 121.4 (4.57), 139.4 (6.72) and 
140.5 (5.84), and diastolic BP mean (SEM) mmHg 72.0 
(2.40), 81.4 (2.54) and 82.88 (2.43) on placebo, angio- 
tensin II 1 ng kg - ’ min - ’ and angiotensin II 
2ngkg-lmin-’ study days, respectively]. However, 
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TABLE 2. Baseline measurements 
Study day 
Ang. II Ang. II 
Screening Placebo lngkgg’minl 2ngkg-‘min-’ 
FEV, 3.18 3.07 3.12 3.01 
(1) (0.34) (0.28) (0.28) (0.30) 
Pulse 62.2 58.5 60.2 62.0 
@pm) (3.1) (2.2) (3.1) (3.4) 
Systolic BP 139.8 132.2 135.2 130.1 
b-W3 (3.9) (2.6) (4.0) (5.5) 
Diastolic BP 79.4 73.8 77.1 73.2 
(mmfk) (2.5) (2.9) (2.2) (2.9) 
0, saturation 96.9 97.1 96.8 96.2 
(%) (0.4) (0.3) (0~2) (0~2) 
Renin 16.9 
@II ml-‘) (7.0) (E) (Z) 
Angiotensin II 
(E) 
7.3 8.2 
bit ml - ‘1 (1.5) (1.9) 
Angiotensin II 
(molar concentration) 7.3 X 10-9M 7.0 x 10 -9M 7.9 X 10-9M 
Results are expressed as means (SEM). 
No significant difference was found for any of the above parameters between study days. 
FIG. 3. The PC,, histamine (mg ml - ‘) on the 
screening day, following placebo infusion and fol- 
lowing infusion of angiotensin II 1 ng kg - ’ min - ’ 
and2ngkgg’min-‘. Angiotensin II had no effect 
on the PC,, histamine. 
there was no statistically significant difference in 
either systolic or diastolic blood pressure following 
histamine challenge on each study day. 
No significant changes in pulse rate or oxygen 
saturation were noted throughout each study day. 
Plasma angiotensin II was measured at baseline, 
steady state (30 min into the infusion) and following 
completion of the infusion on each study day. On the 
placebo day, angiotensin II levels remained unchanged; 
mean (SEM) [mean molar concentration] baseline 7.6 
(1.6) pgmll’ [7.3 x 10K9~], steady state 5.7 (1.1) 
pg ml- ’ [5.5 x 10 ~ 9 M] and post histamine challenge 
5.4 (0.6) pg ml- ’ [5.2 x 10K9 M]. On both angiotensin 
II study days, plasma levels increased significantly 
(WO.05) after 30 min compared to baseline and 
placebo, more so on the 2 ng kg - ’ min - ’ day and 
remained elevated until the end of the infusion; 7.3 
(1.5) pgmll’ [7.0x 10K9~], 23.8 (3.7) pgml-1 
[2.3 x 10K8~] and 22.0 (4.3) pgmll’ [2.1 x ~O-‘M] 
after angiotensin II 1 ng kg - ’ min - ’ and 8.2 (1.9) 
pgml-’ [7.9 x 10-9M], 46.2 (4.7) pg ml- ’ 
[4.4 x ~O-‘M] and 36.0 (5.2) pgmll’ [3.5 x ~O-‘M] 
after angiotensin II 2 ng kg - ’ min - ’ (Fig. 4). 
No adverse effects were reported by the subjects on 
any of the study days. 
Discussion 
The results of this study show that angiotensin II does 
not affect histamine-induced bronchoconstriction in 
human bronchi either in vitro or in vivo. 
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FIG. 4. Plasma angiotensin II levels (pg ml ~ ‘) 
measured before, during the infusion and following 
histamine challenge testing on each study day. 
*Significant difference from placebo and angiotensin 
II 2 ng kg- ’ min- ’ PcO.05. 
**Significant difference from placebo and angio- 
tensin II 1 ng kg - ’ min - ’ PcO.05. 
(o), placebo; (0) angiotensin II 
(1 ng kg - ’ min - ‘); (0), angiotensin II 
(2ngkgg’min’). 
The intravenous infusion of angiotensin II in these 
in vivo studies resulted in an elevation of plasma 
angiotensin II to a maximum of median (inter- 
quartile range) [molar concentration] 43.9 (36.9-52.4) 
pgml-‘[4.2 X 10K8~](3.5-5.0x lo-‘M)compared 
to maximum levels measured by Millar et al. in asth- 
matic patients of 56 (12-109) pg ml - ’ [5.4 x 10 - ’ M] 
(1.2 x lop8 ~-1.0 x 10K7~) during acute severe 
asthma (1). Therefore, the levels achieved by the in- 
fusion of angiotensin II are physiologically relevant. 
The rise in systolic and diastolic blood pressure dur- 
ing the 1 and 2 ng kg ~ ’ min - ’ angiotensin II infu- 
sions confirms its physiological effect. The plasma 
levels of angiotensin II measured during this study 
were similar to those found in the previous study by 
Millar et al. (7), where angiotensin II potentiated 
methacholine-induced bronchoconstriction. 
As there was no significant effect on spirometry 
following 30 min of the infusion on each study day, it 
can be concluded that the dose of angiotensin II 
administered did not cause bronchoconstriction 
directly. 
The reason for angiotensin II potentiating 
methacholine-induced bronchoconstriction (7) but 
not histamine-induced bronchoconstriction is 
undoubtedly complex and may be multi-factorial. 
The two studies have heterogeneous groups of 
subjects although four subjects took part in both 
studies. The current study group were older [mean 
(SD) age 41 (5.3) years compared to 27 (8) years in the 
study by Millar et al. (7)], but both groups were mild 
asthmatics with mean (SD) FEV, 88 (11) % predicted 
in the current study and 82 (9) % predicted in the 
study by Millar et al. (7). Bronchial reactivity during 
placebo infusion was similar in both groups with 
geometric mean (range) PC,, histamine 2.67 (0.89- 
9.57) mg ml - ’ in the current study and PC,, metha- 
choline 3.09 (1.15-6.0) mg ml - ’ in the study by 
Millar et al. (7). Therefore, it is unlikely that variation 
in patient selection between these two studies has 
accounted for the different effect of angiotensin II 
on histamine- and methacholine-induced broncho- 
constriction in vivo. 
It is possible that, in asthmatics with greater 
bronchial reactivity the effect of angiotensin II on 
histamine-induced bronchoconstriction may be dif- 
ferent due to more local inflammation, the presence 
of higher levels of mediators or a greater volume of 
airway smooth muscle. However, it is established that 
in mild asthmatics angiotensin II can potentiate the 
effect of methacholine, thus it appears that there is a 
fundamental difference between the interaction of 
angiotensin II with methacholine and histamine. 
The lack of interaction between angiotensin II and 
histamine in the human airway could be explained by 
the absence of functional angiotensin II receptors in 
the bronchi. However, although no direct evidence 
exists demonstrating tissue-specific angiotensin II 
receptors in the lungs, Curnow et al. (14) have 
extracted type-l angiotensin II (AT,) receptor 
mRNA from human lung tissue. Both type- 1 (15) and 
type-2 (16) angiotensin II receptor mRNA has also 
been identified in foetal rat lung. 
Studies on bronchial reactivity in vitro in bovine 
bronchial rings have shown an AT, receptor- 
mediated potentiating effect of angiotensin II on 
endothelin-l-evoked bronchoconstriction (8). Al- 
though the mild bronchoconstrictor effect of angio- 
tensin II on asthmatic airways in vivo (1) and its 
potentiating effect on methacholine-induced bron- 
choconstriction on human bronchi both in vitro and in 
vivo (7) have not been proven to be receptor-specific 
phenomena, it is likely that functional angiotensin II 
receptors do exist in the human airway. 
The reason for the lack of potentiating effect of 
angiotensin II in relation to histamine may relate to 
differing second messenger intracellular pathways 
and varied cross-talk between pathways. The effect of 
angiotensin II on intracellular pathways in airway 
smooth muscle remains to be characterized. However, 
in vascular tissue, the type-l angiotensin II receptor is 
coupled to a G-protein activating phospholipase-C 
and liberating diacylglycerol (DAG) and inositol 
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triphosphate (IP,), resulting in a rise in intracellular 
calcium concentration (17). In some tissues, the angio- 
tensin II receptor is also coupled to an inhibitory 
G-protein which inhibits adenylate cyclase (18). 
Histamine exerts its effects on airway smooth 
muscle via the Hi receptor which is also coupled to a 
G-protein activating phospholipase C and liberating 
DAG and IP, (19). The increase in IP, is inhibited by 
cyclic adenosine-monophosphate (CAMP), attenuat- 
ing the histamine-induced increase in intracellular 
calcium in canine airway smooth muscle (19). 
Cholinergic muscarine receptors in the airways are 
also coupled to membrane phospholipid hydrolysis to 
form IP, but this occurs by a different pathway which 
is insensitive to CAMP (19). 
Therefore, cross-talk at the second messenger level 
between angiotensin II intracellular pathways and 
histamine and acetyl choline/methacholine second 
messenger pathways could have different end results. 
The final site of potential interaction is at the recep- 
tor level itself. Angiotensin II uncovers previously 
silent a2- adrenoceptors in the rabbit distal saphenous 
artery (5) and if a similar interaction occurred be- 
tween receptors for different spasmogens in airway 
smooth muscle this could lead to potentiation. 
In conclusion, the role of the renin-angiotensin 
system in asthma is still incompletely understood. It 
seems that angiotensin II interacts diversely with 
different bronchoconstrictors potentiating the effects 
of methacholine and endothelin-1 but not histamine 
in the airway. 
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